MAYOLY has reached a new milestone in its industrial and healthcare sovereignty strategy by relocating the production of colchicine, an essential treatment for gout, to its Auxerre site (Galien – Bourgogne-Franche-Comté).
Used by approximately 600,000 patients, colchicine is a critical medicine whose supply security is of major importance. In a context of global supply chain tensions, this relocation will help sustainably secure the production and distribution of this essential treatment.
The project includes a €2.5 million investment to bring this strategic production back in-house in France and will contribute to:
- supporting employment and industrial expertise in local communities;
- promoting responsible, competitive and sustainable French manufacturing;
- strengthening industrial autonomy and healthcare sovereignty.
Today, 85% of MAYOLY’s products are manufactured in France, the Group operates in more than 100 countries worldwide, and generates over €400 million in exports.
The announcement was widely covered by both national and regional media, including Le Monde, La Tribune, Le Figaro, France 3 Régions, 20 Minutes, Sud Ouest, Nice-Matin, L’Usine Nouvelle, Challenges, France Bleu Auxerre, L’Yonne Républicaine, Économie Matin and Boursorama.
Article Le Monde
Article La Tribune
Article Le Figaro
Article Challenges
Article L’Usine Nouvelle
Article 20minutes
Article France 3 Régions
Article l’Yonne Républicaine
Article Sud Ouest
Article Nice Matin
Article Radio France
No comments yet, be the first to comment.